



**FOR 9:00 AM (EST) RELEASE**

Contact:

Aegera Therapeutics Inc.  
514-288-4091, x225  
Catherine So  
Manager, Business Development  
Email: [catherine.so@aegea.com](mailto:catherine.so@aegea.com)

**AEGERA THERAPEUTICS APPOINTS DR. JACQUES JOLIVET AS VICE PRESIDENT OF CLINICAL DEVELOPMENT**

**MONTREAL, July 6, 2005** - Aegera Therapeutics Inc., a clinical stage biotechnology company uniquely focused on apoptosis control, is pleased to announce the appointment of Dr. Jacques Jolivet, M.D., to its executive team as Vice President, Clinical Development.

Dr. Jolivet brings to Aegera over 20 years of expertise as both a corporate executive as well as a practicing clinical oncologist. Prior to joining Aegera, Dr. Jolivet served as Director of Clinical Development, Oncology at Shire Pharmaceuticals and its predecessor, BioChem Pharma, where he played a key role in the development of Troxatyl™. Dr. Jolivet maintains a part time clinical oncology practice at the Hematology and Medical Oncology department of the Hotel Dieu Hospital of St.-Jérôme.

Dr. Jolivet received his medical degree from l'Université de Montréal, and completed his residency in internal medicine at the Royal Victoria Hospital. He completed a 3-year fellowship in anticancer drug pharmacology at the National Cancer Institute in Bethesda, MD. Dr. Jolivet led a research laboratory at the University of Montreal for 15 years, and has received numerous grants and awards for his research culminating in two issued US patents and more than 80 published papers.

"Dr. Jolivet is an excellent addition to our team. His experience in directing oncology clinical trials and working with the FDA, Health Canada and other international regulatory agencies will be invaluable as we advance the Phase 1 and 2 clinical trials of our lead products including our anticancer drug AEG35156 and our supportive care drug AEG33783," commented Michael Atkin, Aegera's President and CEO. Aegera's lead drug, AEG35156, is an antisense therapeutic targeting Aegera's proprietary XIAP gene, and is presently in phase I clinical trials in the UK, Canada and the U.S. Aegera's second drug candidate, AEG33783, for the treatment of chemotherapy side effects will begin clinical trials in Q1, 2006.

**About Aegera**

Aegera Therapeutics Inc. is a private North American biotechnology company focused on exploiting apoptosis control to extend and enhance the lives of cancer patients: killing cancer cells by inducing apoptosis and rescuing neurons from apoptotic cell death. Aegera's lead oncology product, AEG35156, is designed to restore apoptosis pathways by inhibiting Aegera's proprietary target, XIAP, and is now in clinical trials. Aegera's second product, AEG33783, is being developed to alleviate the disabling chemotherapy side-effect of peripheral neuropathy, and is scheduled to enter clinical trials early in 2006. For more information, please visit Aegera's website at [www.aegera.com](http://www.aegera.com).

